Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to determine if a weekly dose of 17 hydroxyprogesterone
caproate (17P, Makena®) given to women with preterm rupture of the membranes will:
1. increase the probability of continuing the pregnancy until a favorable gestational age.
2. increase the interval between randomization and delivery.
3. decrease neonatal morbidity.